As the world’s first and only highly selective JAK1 inhibitor, golidocitinib demonstrates significant efficacy in relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) with a lower risk of off-target adverse reactions.
Authentic
Guarantee
Fast Delivery
Privacy Golidocitinib, a novel Janus kinase (JAK) inhibitor, is primarily indicated for the treatment of relapsed or refractory T-cell lymphoma and other hema···【Read More】
Update: 06 Feb,2026Source: Haiou HealthViews: 73
Golidocitinib is a targeted therapy indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma (rPTCL). Following the implementa···【Read More】
Update: 06 Feb,2026Source: Haiou HealthViews: 73
Golidocitinib Capsules are primarily indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma. Its current market price is app···【Read More】
Update: 06 Feb,2026Source: Haiou HealthViews: 73
Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH



